These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8016393)

  • 41. Erythrocyte morphologic features and serum chemistry studies in ovine pregnancy-induced hypertension treated with thromboxane synthetase inhibitors.
    Miller KW; Keith JC
    Am J Obstet Gynecol; 1988 Nov; 159(5):1241-6. PubMed ID: 3189458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between umbilical artery resistance index, 6 ketoprostaglandin F1 alpha and thromboxane B2 in the fetoplacental compartment in patients with pregnancy induced hypertension.
    Mahmoud TZ; Bjornsson S; Kelly RW; Calder AA
    Prostaglandins; 1993 Jun; 45(6):509-15. PubMed ID: 8337411
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostacyclin in pregnancy.
    Spitz B; Deckmyn H; Van Assche FA; Vermylen J
    Eur J Obstet Gynecol Reprod Biol; 1984 Dec; 18(5-6):303-8. PubMed ID: 6441731
    [No Abstract]   [Full Text] [Related]  

  • 44. The effects of a new thromboxane synthetase inhibitor, CGS-13080, in man.
    MacNab MW; Foltz EL; Graves BS; Rinehart RK; Tripp SL; Feliciano NR; Sen S
    J Clin Pharmacol; 1984; 24(2-3):76-83. PubMed ID: 6371062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin.
    Tranchesi B; Pileggi F; Vercammen E; Van de Werf F; Verstraete M
    Eur Heart J; 1994 May; 15(5):660-4. PubMed ID: 8056007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do prostacyclin and thromboxane play a role in endotoxic shock?
    Webb PJ; Westwick J; Scully MF; Zahavi J; Kakkar VV
    Br J Surg; 1981 Oct; 68(10):720-4. PubMed ID: 7025959
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
    Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
    Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
    Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
    Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
    De La Cruz JP; Moreno A; Ruiz-Ruiz MI; Sánchez De La Cuesta F
    Thromb Res; 2000 Feb; 97(3):125-31. PubMed ID: 10680643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models.
    Ku EC; McPherson SE; Signor C; Chertock H; Cash WD
    Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis.
    Vilaseca J; Salas A; Guarner F; Rodriguez R; Malagelada JR
    Gastroenterology; 1990 Feb; 98(2):269-77. PubMed ID: 2153086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preliminary observations of the acute effects of selective serum thromboxane inhibition and angiotensin converting enzyme inhibition on blood pressure and renal hemodynamics in hypertensive humans.
    Weir MR; Klassen DK; Hoover N; Douglas FL
    J Clin Pharmacol; 1989 Dec; 29(12):1108-16. PubMed ID: 2693500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
    Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
    J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased skin flap viability after treatment with forskolin or with ridogrel, a thromboxane synthesis inhibitor and receptor blocker.
    Banić A; Kouris K; Rajacić N; Nazal M; Thulesius O
    Res Exp Med (Berl); 1990; 190(3):223-7. PubMed ID: 2142328
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostacyclin and thromboxane in pregnancy-induced hypertension.
    Yang CS; Zhang LZ
    Chin Med J (Engl); 1988 Dec; 101(12):906-10. PubMed ID: 3150739
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
    de Chaffoy de Courcelles D; De Clerck F
    Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs.
    DeCampli WM; Goodwin D; Kosek JC; Handen CE; Mitchell RS; Miller DC
    Ann Thorac Surg; 1986 Dec; 42(6):690-6. PubMed ID: 3789860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery.
    Kim YD; Foegh ML; Wallace RB; Ng L; Ahmed SW; Katz NM; Siegelman R; Franco K; Douglas F; Ku E
    Circulation; 1988 Sep; 78(3 Pt 2):I44-50. PubMed ID: 3409518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.